Psyence Biomedical Ltd.(PBM)Earnings, Financials & Key Ratios
PBM•NASDAQ
Price updated Jun 19, 2026
AboutPsyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Show more
- Revenue$0
- EBITDA-$3M-112.6%
- Net Income-$51M-738.3%
- EPS (Diluted)-7.85-1126.6%
- ROE-43.78%-1414.8%
PBM Key Insights
Psyence Biomedical Ltd. (PBM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 80.1% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PBM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PBM Price & Volume
Psyence Biomedical Ltd. (PBM) stock price & volume — 10-year historical chart
Loading chart...
PBM Growth Metrics
Psyence Biomedical Ltd. (PBM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-418.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-827.11%
Return on Capital
10 Years-1%
5 Years-1%
3 Years-1%
Last Year-2.36%
PBM Peer Comparison
Psyence Biomedical Ltd. (PBM) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 LSCC | 21.06B | 153.72 | 6893.27 | 2.72% | 3.46% | 2.79% | 0.11 | |
 SILO | 5.54M | 6.12 | -0.82 | -67.17% | -88.41% | |||
 ENVB | 764.17K | 1.28 | -0.04 | -220.99% | ||||
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare PBM vs Peers
Psyence Biomedical Ltd. (PBM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PBM Income Statement
Psyence Biomedical Ltd. (PBM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'22 | Mar'23 | Mar'24 | TTM |
|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 240 | 0 |
COGS % of Revenue | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -240▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - |
Gross Profit Growth % | - | - | - | - |
Operating Expenses | 334.29K | 1.29M | 2.75M | 2.47M |
OpEx % of Revenue | - | - | - | - |
Selling, General & Admin | 1.72M | 1.63M | 1.8M | 2.4M |
SG&A % of Revenue | - | - | - | - |
Research & Development | 137.24K | 1.61M | 954.59K | 75.14K |
R&D % of Revenue | - | - | - | - |
Other Operating Expenses | -1.52M | -1.94M | 0 | 0 |
Operating Income | -334.29K▲ 0% | -1.29M▼ 287.1% | -2.75M▼ 112.7% | -2.47M▲ 0% |
Operating Margin % | - | - | - | - |
Operating Income Growth % | - | -287.08% | -112.66% | - |
EBITDA | -334.29K | -1.29M | -2.75M | -2.47M |
EBITDA Margin % | - | - | - | - |
EBITDA Growth % | - | -287.08% | -112.65% | -91.09% |
D&A (Non-Cash Add-back) | 0 | 0 | 240 | 120 |
EBIT | 0 | 0 | -51.11M | -893.4K |
Net Interest Income | 0 | 1.55K | -50.81K | 645.88K |
Interest Income | 0 | 1.55K | 2.13K | 673.45K |
Interest Expense | 0 | 0 | 52.94K | 27.57K |
Other Income/Expense | 8.56M | 9.31M | -48.41M | -23.03M |
Pretax Income | 8.23M▲ 0% | 8.01M▼ 2.6% | -51.16M▼ 738.3% | -25.5M▲ 0% |
Pretax Margin % | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% |
Net Income | 8.23M▲ 0% | 8.01M▼ 2.6% | -51.16M▼ 738.3% | -25.5M▲ 0% |
Net Margin % | - | - | - | - |
Net Income Growth % | - | -2.63% | -738.35% | -418.16% |
Net Income (Continuing) | 8.23M | 8.01M | -51.16M | -25.5M |
Discontinued Operations | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.25▲ 0% | -0.64▼ 356.0% | -7.85▼ 1126.6% | -1.90▲ 0% |
EPS Growth % | - | -356% | -1126.56% | -827.11% |
EPS (Basic) | 0.25 | -0.64 | -7.85 | - |
Diluted Shares Outstanding | 32.67M | 32.67M | 6.52M | 13.39M |
Basic Shares Outstanding | 32.67M | 32.67M | 6.52M | 13.39M |
Dividend Payout Ratio | - | - | - | - |
PBM Balance Sheet
Psyence Biomedical Ltd. (PBM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'22 | Mar'23 | Mar'24 | TTM |
|---|---|---|---|---|
Total Current Assets | 797.2K | 1.21M | 1.13M | 1.13K |
Cash & Short-Term Investments | 431.9K | 15.96K | 762.8K | 733 |
Cash Only | 648.28K | 128.68K | 762.8K | 733 |
Short-Term Investments | 0 | 0 | 0 | 0 |
Accounts Receivable | 39.55K | 60.9K | 41.75K | 0 |
Days Sales Outstanding | - | - | - | - |
Inventory | -39.55K | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - |
Other Current Assets | 0 | 917.12K | 0 | 71 |
Total Non-Current Assets | 255.25M | 257.73M | 5.49K | 5 |
Property, Plant & Equipment | 0 | 0 | 5.49K | 5 |
Fixed Asset Turnover | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 |
Long-Term Investments | 255M | 257.73M | 0 | 45.18M |
Other Non-Current Assets | 248.65K | 0 | 0 | 0 |
Total Assets | 256.22M▲ 0% | 258.93M▲ 1.1% | 1.13M▼ 99.6% | 1.13K▲ 0% |
Asset Turnover | - | - | - | 0.00x |
Asset Growth % | - | 1.06% | -99.56% | -382.11% |
Total Current Liabilities | 68.7K | 14.27M | 12.1M | 12.1K |
Accounts Payable | 36.89K | 1.63M | 562.35K | 562 |
Days Payables Outstanding | - | - | 855.24K | - |
Short-Term Debt | 0 | 685K | 10.45M | 10.45K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
Other Current Liabilities | -63.06K | 11.8M | 968.51K | 969 |
Current Ratio | 11.60x | 0.08x | 0.09x | 0.09x |
Quick Ratio | 12.18x | 0.08x | 0.09x | 0.09x |
Cash Conversion Cycle | - | - | - | - |
Total Non-Current Liabilities | 16.24M | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16.24M | 0 | 0 | 0 |
Total Liabilities | 19.58M | 14.27M | 12.1M | 12.1K |
Total Debt | 0 | 685K | 10.45M | 10.45K |
Net Debt | -648.28K | -128.68K | 9.71M | 9.71K |
Debt / Equity | - | 0.00x | - | -0.95x |
Debt / EBITDA | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | -0.00x |
Interest Coverage | - | - | -51.98x | -32.41x |
Total Equity | 236.65M▲ 0% | 244.66M▲ 3.4% | -10.97M▼ 104.5% | -10.97K▲ 0% |
Equity Growth % | - | 3.39% | -104.48% | -400.21% |
Book Value per Share | 7.24 | 7.49 | -1.68 | -0.00 |
Total Shareholders' Equity | 236.65M | 244.66M | -10.97M | -10.97K |
Common Stock | 255M | 258.55M | 46.13M | 46.13K |
Retained Earnings | -18.36M | -13.9M | -57.46M | -57.46K |
Treasury Stock | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 361.06K | 361 |
Minority Interest | 0 | 0 | 0 | 0 |
PBM Cash Flow Statement
Psyence Biomedical Ltd. (PBM) cash flow — operating, investing & free cash flow history
| Metric | Mar'22 | Mar'23 | Mar'24 | TTM |
|---|---|---|---|---|
Cash from Operations | -1.4M | -519.6K | -2.95M | -1.05M |
Operating CF Margin % | - | - | - | - |
Operating CF Growth % | - | 62.79% | -466.85% | -329.65% |
Net Income | -1.86M | -24.49K | -51.16M | -25.5M |
Depreciation & Amortization | 0 | 0 | 240 | 0 |
Stock-Based Compensation | 332.07K | 221.29K | 317.88K | 159 |
Deferred Taxes | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | -661.96K | 49.07M | -1.85M |
Working Capital Changes | 129.74K | -54.44K | -1.17M | 787.37K |
Change in Receivables | 100.05K | 0 | 107.62K | 767.9K |
Change in Inventory | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 |
Cash from Investing | -32.04K | 0 | -5.73K | 246.83M |
Capital Expenditures | 0 | 0 | -5.73K | -4 |
CapEx % of Revenue | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 |
Investments | - | - | - | - |
Other Investing | 254.97M | 0 | 0 | 0 |
Cash from Financing | -1.63M | 1.17M | 2.35M | -245.81M |
Debt Issued (Net) | 0 | 0 | 2.35M | 0 |
Equity Issued (Net) | 0 | 0 | 0 | -2M |
Dividends Paid | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -247.42M |
Other Financing | -1.63M | 1.17M | 0 | 1.61M |
Net Change in Cash | -3.06M▲ 0% | -519.61K▲ 83.0% | -601.09K▼ 15.7% | -40.43K▲ 0% |
Free Cash Flow | -839.17K▲ 0% | -519.6K▲ 38.1% | -2.95M▼ 468.0% | -1.05M▲ 0% |
FCF Margin % | - | - | - | - |
FCF Growth % | - | 38.08% | -467.95% | -102.8% |
FCF per Share | -0.03 | -0.02 | -0.45 | -0.08 |
FCF Conversion (FCF/Net Income) | -0.17x | -0.06x | 0.06x | 0.04x |
Interest Paid | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 |
PBM Key Ratios
Psyence Biomedical Ltd. (PBM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | TTM |
|---|---|---|---|
Return on Equity (ROE) | 3.33% | -43.78% | 19522.88% |
Return on Invested Capital (ROIC) | -0.4% | -1.69% | -260.85% |
Debt / Equity | 0.00x | - | -0.95x |
Interest Coverage | - | -51.98x | -32.41x |
FCF Conversion | -0.06x | 0.06x | 0.04x |
Related:PBM Dividend History·PBM Revenue History·PBM Price History·PBM P/E History·PBM Financial Ratios·PBM Institutional Holders
PBM Frequently Asked Questions
Psyence Biomedical Ltd. (PBM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Psyence Biomedical Ltd. (PBM) grew revenue by 0.0% over the past year. Growth has been modest.
Psyence Biomedical Ltd. (PBM) reported a net loss of $25.5M for fiscal year 2023.
Dividend & Returns
Psyence Biomedical Ltd. (PBM) has a return on equity (ROE) of -43.8%. Negative ROE indicates the company is unprofitable.
Psyence Biomedical Ltd. (PBM) had negative free cash flow of $1.1M in fiscal year 2023, likely due to heavy capital investments.